ARP Americas LP Takes Position in ABIOMED, Inc. (ABMD)

ARP Americas LP bought a new position in ABIOMED, Inc. (NASDAQ:ABMD) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 698 shares of the medical equipment provider’s stock, valued at approximately $227,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ABMD. AQR Capital Management LLC grew its holdings in shares of ABIOMED by 193.5% in the 3rd quarter. AQR Capital Management LLC now owns 1,207,996 shares of the medical equipment provider’s stock worth $543,297,000 after acquiring an additional 796,482 shares during the last quarter. BlackRock Inc. grew its holdings in shares of ABIOMED by 10.3% in the 3rd quarter. BlackRock Inc. now owns 3,117,569 shares of the medical equipment provider’s stock worth $1,402,127,000 after acquiring an additional 290,298 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of ABIOMED by 5.9% in the 3rd quarter. Vanguard Group Inc now owns 4,647,227 shares of the medical equipment provider’s stock worth $2,090,091,000 after acquiring an additional 260,829 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of ABIOMED by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,647,227 shares of the medical equipment provider’s stock worth $2,090,091,000 after acquiring an additional 260,829 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of ABIOMED by 90.1% in the 3rd quarter. Janus Henderson Group PLC now owns 517,612 shares of the medical equipment provider’s stock worth $232,797,000 after acquiring an additional 245,286 shares during the last quarter. Institutional investors and hedge funds own 86.96% of the company’s stock.

A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded ABIOMED from a “hold” rating to a “buy” rating and set a $370.00 target price on the stock in a report on Friday, January 18th. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a report on Friday, December 28th. ValuEngine cut ABIOMED from a “buy” rating to a “hold” rating in a report on Wednesday, February 27th. Finally, Morgan Stanley decreased their target price on ABIOMED from $496.00 to $461.00 and set an “overweight” rating on the stock in a report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. ABIOMED has a consensus rating of “Buy” and an average target price of $421.00.

In other news, COO David M. Weber sold 24,000 shares of ABIOMED stock in a transaction on Friday, January 25th. The stock was sold at an average price of $351.47, for a total transaction of $8,435,280.00. Following the transaction, the chief operating officer now owns 161,842 shares in the company, valued at $56,882,607.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Martin P. Sutter sold 20,000 shares of ABIOMED stock in a transaction on Friday, February 15th. The shares were sold at an average price of $360.16, for a total value of $7,203,200.00. Following the transaction, the director now owns 195,491 shares in the company, valued at approximately $70,408,038.56. The disclosure for this sale can be found here. Insiders have sold 74,928 shares of company stock worth $26,515,812 in the last quarter. 3.50% of the stock is currently owned by corporate insiders.

Shares of ABMD stock opened at $325.61 on Friday. ABIOMED, Inc. has a 1-year low of $274.02 and a 1-year high of $459.75. The firm has a market cap of $14.66 billion, a PE ratio of 132.90, a price-to-earnings-growth ratio of 3.27 and a beta of 0.37.

ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. ABIOMED had a return on equity of 20.31% and a net margin of 30.12%. The business had revenue of $200.56 million for the quarter, compared to the consensus estimate of $200.60 million. As a group, analysts expect that ABIOMED, Inc. will post 3.58 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ARP Americas LP Takes Position in ABIOMED, Inc. (ABMD)” was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of international copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/2019/03/15/arp-americas-lp-takes-position-in-abiomed-inc-abmd.html.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Read More: How Do Tariffs Affect Trade Balances?

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.